Form 4: STERIS plc Executive Increases Stake with New Share and Option Grants

Cary L. Majors, SVP and President of Healthcare at STERIS plc, reported an increase in beneficial ownership through the acquisition of ordinary shares and employee stock options.

Summary

• Cary L. Majors, SVP and President, Healthcare of STERIS plc, acquired 2,922 ordinary shares and 10,392 employee stock options on June 3, 2025.
• The acquired ordinary shares were granted at a price of $0, indicating a likely vesting or compensation grant.
• The employee stock options have an exercise price of $267.66 and expire on June 3, 2035.
• A small disposition of 67 ordinary shares was also reported, likely related to tax withholding or a minor transaction.
• Following these transactions, Mr. Majors directly beneficially owns 13,730 ordinary shares and 10,392 employee stock options.
• Additionally, 67 ordinary share equivalents are held indirectly on behalf of Mr. Majors under the STERIS Corporation 401(k) Plan as of June 2, 2025.
• Of the directly held ordinary shares, 10,830 are restricted, with vesting scheduled between October 1, 2025, and June 5, 2028.
• The newly acquired employee stock options will become exercisable in four equal annual installments of 2,598 options, starting June 3, 2026, through June 4, 2029.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects a routine compensation event where a key executive increases their stake in the company, aligning their interests with shareholders. There are no negative operational or financial implications indicated.

Positives

• The acquisition of 2,922 ordinary shares and 10,392 employee stock options by a key executive indicates continued alignment of management's interests with shareholder value.
• The grants are part of executive compensation, which can incentivize long-term performance and retention of key personnel.

Negatives

• A disposition of 67 ordinary shares was reported, though this is a small amount and likely related to routine compensation adjustments or tax obligations.

Future Outlook

This Form 4 primarily details past and scheduled future vesting events related to executive compensation, rather than providing a forward-looking statement on company performance or strategic guidance.

Industry Context

This filing is a routine disclosure of insider transactions, common across all publicly traded companies, reflecting executive compensation practices. It does not provide specific insights into broader industry trends or competitive dynamics beyond the company's internal compensation structure.

Stakeholder Impact

• Shareholders: The increase in executive ownership through compensation grants can be viewed positively as it aligns management's interests with long-term shareholder value.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation practices for senior leadership.

Next Steps

• Vesting of 692 restricted ordinary shares on October 1, 2025.
• Vesting of 2,697 restricted ordinary shares on June 1, 2026.
• Vesting of 2,140 restricted ordinary shares on June 2, 2026.
• First tranche of 2,598 employee stock options becoming exercisable on June 3, 2026.
• Subsequent annual vesting of employee stock options on June 3, 2027, June 3, 2028, and June 4, 2029.
• Vesting of 2,379 restricted ordinary shares on June 4, 2027.
• Vesting of 2,922 restricted ordinary shares on June 5, 2028.

Key Dates

Keywords

STERIS plc, STE, Form 4, Insider Transaction, Beneficial Ownership, Stock Options, Executive Compensation, Share Grant, Restricted Stock